Skip to contents

Elliott Marshall Antman
Senior Physician, Brigham and Women's Hospital
Associate Dean for Clinical and Translational Research, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
75 Francis Street
Boston, MA 02115

Edit Profile

Research Narrative:

Dr. Elliott Antman's research interests involve the clinical pharmacology of cardiovascular agents and their evaluation in randomized control trials. Dr. Antman is a Senior Investigator in the TIMI Study Group and is leading projects evaluating novel antithrombotic agents, especially for the management of acute coronary syndromes. Utilizing biostatistical techniques such as meta-analysis, the efficacy and safety of various agents are being evaluated. Dr. Antman is the immediate past chair of the ACC/AHA Task Force on Practice Guidelines and remains involved in the writing of the UA/STEMI and STEMI Guidelines. He is a member of the Board of Trustees of the American College of Cardiology and the Science Advisory and Coordinating Committee of the American Heart Association.

Publications (Pulled from Harvard Catalyst Profiles):

1. Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension. 2019 Sep; 74(3):597-605.

2. Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. J Am Coll Cardiol. 2019 Jul 16; 74(2):179-189.

3. Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 May 14; 40(19):1518-1527.

4. Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 May 14; 40(19):1541-1550.

5. Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019 Feb 05; 139(6):760-771.

6. Steffel J, Ruff CT, Braunwald E, Hamershock RA, Murphy SA, Nieminen M, Lanz HJ, Mercuri MF, Peterson N, Antman EM, Giugliano RP. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace. 2019 Feb 01; 21(2):306-312.

7. Granger CB, Bates ER, Jollis JG, Antman EM, Nichol G, O'Connor RE, Gregory T, Roettig ML, Peng SA, Ellrodt G, Henry TD, French WJ, Jacobs AK. Improving Care of STEMI in the United States 2008 to 2012. J Am Heart Assoc. 2019 Jan 08; 8(1):e008096.

8. Correction. J Am Coll Cardiol. 2019 Feb 12; 73(5):627.

9. Antman EM. Improving care at the population and individual level: lessons from SWEDEHEART. Eur Heart J. 2018 Nov 07; 39(42):3777-3779.

10. Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP. Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 07; 39(42):3810-3820.